Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble Suppression of Tumorigenesis-2 for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV)

Launched by ISTITUTO NAZIONALE DI RICOVERO E CURA PER ANZIANI · Mar 24, 2025

Keywords

ClinConnect Summary

The Diabetes-CV study is looking at how certain blood tests can help predict serious health issues in people with type 2 diabetes. Specifically, researchers are examining three markers in the blood: high-sensitivity cardiac troponin I (hs-cTnI), N-terminal pro-B-natriuretic peptide (NT-proBNP), and soluble suppression of tumorigenesis-2 (sST2). These markers could provide important information about a person's risk of dying, having major heart problems, or experiencing complications related to diabetes.

To participate in this study, individuals must be 18 years or older and have type 2 diabetes. Unfortunately, those with type 1 diabetes, current cancer, or cancer that was treated less than five years ago cannot join. Participants will be asked to visit outpatient services for evaluations and blood tests. This research aims to improve our understanding of how to better manage heart health in people with diabetes, potentially leading to better outcomes for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • type 2 diabetes
• • patients attending the outpatient services
• Exclusion Criteria:
• • type 1 diabetes
• • patients with active cancer or cancer in remission for less than 5 years
• • any medical or other reason that leads the investigator to consider the subject ineligible for the study.